劳拉替尼 Lorlatinib Lorlatinib, also known as PF-06463922, is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1)

塞瑞替尼 Ceritinib Ceritinib, also known as LDK378, is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC).

布格替尼 Brigatinib Brigatinib, also known as AP-26113, is an orally active, potent and selective Dual ALK/EGFR inhibitor.

艾乐替尼 Alectinib Alectinib, also known as AF802, or CH5424802 or RO5424802, is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold

瑞格非尼 Regorafenib Regorafenib, also known as BAY 73-4506 ; is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities.

舒尼替尼 Sunitinib Sunitinib free base is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor.